microEEG for Neonatal Apnea, Bradycardia and Desaturation

NCT ID: NCT02436616

Last Updated: 2016-02-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-31

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study utilizes microEEG (a novel miniaturized, FDA approved EEG device) to prospectively investigate the cerebral electrical activity of infants with Apnea, Bradycardia and Desaturation events. This project will also assess the feasibility of using the microEEG device in the Neonatal Intensive Care Unit (NICU) setting and the feasibility of remote centralized interpretation in this setting.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Most preterm infants have episodes of apnea (cessation of breathing), bradycardia (low heart rate), and desaturations (low levels of oxygen in the blood) (ABD events). The resolution of ABD episodes depends to a large extent on the maturation of the central nervous system (CNS). The electroencephalogram (EEG) is a reliable and noninvasive tool for recording the electrical activity of the CNS. The relationship between ABD events and cerebral electrical activity has not been well investigated. The investigators seek to examine the relationship between EEG findings and the resolution of ABD events in the developing premature infant.

To investigate this relationship and obtain findings which are relevant to clinical care, a variety of obstacles need to be overcome. Among these obstacles is the high cost of standard EEG machines, inability of most standard machines to operate in electrically-noisy environments such as the NICU, and the absence of full-time coverage neurologists for prompt EEG interpretation. The investigators seek to determine the feasibility of obtaining an artifact-free EEG in the NICU with accurate detection of background rhythm abnormalities. The investigators will utilize an existing digital wireless telemetry unit, the "microEEG" for the NICU for this purpose. The microEEG device is specifically designed to overcome obstacles to standard EEG recording.

To address the shortage of trained pediatric neurophysiologists, the investigators will investigate the feasibility of a case management system for centralized EEG interpretation using off-site neurologists.

Finally, the investigators will examine the inter-rater reliability of EEG interpretation in the developing premature infant. This will allow the development of consensus guidelines for EEG interpretations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Apnea Bradycardia Premature Birth Seizures

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

EEG Preterm Infants Neonate wireless

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EEG monitoring

All subjects enrolled in this observational study will undergo EEG monitoring using the microEEG device.

microEEG

Intervention Type DEVICE

microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).

If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

microEEG

microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).

If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. gestational age (GA) 24-32 weeks
2. postnatal ages 0-30 days. The patients will be recruited upon manifesting one of the following

* apneas (cessation of breathing \> 10 seconds) x2 in a 12 hour span
* bradycardias (HR \< 100/min) x2 in 12 hours
* oxygen desaturations (\<80%) x 2 in 12 hours
* a single ABD event that does not resolve with stimulation or an increase in fractional oxygen delivery (FiO2).

Exclusion Criteria

1. major malformations
2. The infant has exposed dermis on the scalp due to immaturity
3. Any scalp skin lesions such as pustules, large abrasions The patient will be Withdrawn if

* Informed consent is withdrawn
* adverse events (i.e..scalp lesions) develop
Maximum Eligible Age

30 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

State University of New York - Downstate Medical Center

OTHER

Sponsor Role collaborator

Brookdale University Hospital Medical Center

OTHER

Sponsor Role collaborator

Bio-Signal Group Corp.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zachary Ibrahim, MD

Role: PRINCIPAL_INVESTIGATOR

State University of New York - Downstate Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

State University of New York/Downstate Medical Center

Brooklyn, New York, United States

Site Status RECRUITING

Brookdale University Hospital and Medical Center,

Brooklyn, New York, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Samah Abdel Baki, MD

Role: CONTACT

Phone: 3473460729

Email: [email protected]

Zachary Ibrahim, MD

Role: CONTACT

Phone: 9172184700

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zachary Ibrahim, MD

Role: primary

Geetha Chari, MD

Role: backup

Roger Kim, MD

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

http://icnapedia.org/icnc/index.php/icnc/2014/paper/view/585

Abstract from International Chil Neurology Congress

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

307016-7

Identifier Type: -

Identifier Source: org_study_id